

TUMOUR GROWTH PARAMETER ESTIMATION FROM DOUBLING TIMES

Mohammed Arshad Ali*

Ahmed Waheedullah**

Abstract

Awareness of tumour growth characteristics is important in treatment of deadly disease Cancer. Experiments take lengthy time to explore the characteristics and availability of required sample size is another drawback in making conclusions about tumour growth characteristics. Mathematical modeling and statistical theory facilitates in predicting results without conducting experiments practically and making inferences about tumour growth parameters from sample characteristics. In this paper, the proliferation rates and interval estimates of proliferation rates with different confidence levels of various human cancer tumours were estimated with the help of tumour growth equation and sampling theory using doubling times from experimental data.

Copyright © 2017 International Journals of Multidisciplinary Research Academy. All rights reserved.

Keywords:

Proliferation rate;
Tumour doubling time;
Tumour growth parameter;
Cell proliferation;
Tumour spheroid growth.

Author correspondence:

Mohammed Arshad Ali,
Associate Professor, Deccan school of Management, Hyderabad, India.

1. Introduction

Cancer is a deadly disease with a symptom of abnormal and uncontrolled growth of tissue at any part of the human body. The characteristics of tumours such as location, stage of the tumour, size and nature of the tumour cells plays very important role in treatment of Cancer. If the growth of the tumour is very rapid, it could be dangerous to the patient. If tumour cells reach another place through blood vessels, it will initiate a new growth at different place of the body in addition to the already grown tumour at previous site. In the fast growing tumours, delay in treatment may lead to further tumour growth and complications in the patients. The early treatment may reduce the chances of metastasis and increase the chances of cure and survival of the patient. The tumour doubling time is one such character which indicates time taken by the tumour to double its size or volume will be helpful in treating cancer. Doubling times varies from tissue to tissue depending upon the nature of the tissue cells. In Mathematical terminology, another parameter, the rate at which tumor cells grow or multiply themselves is known as proliferation rates can be estimated from tumour doubling times by considering the tumour in a spherical shape. With the information of a specific character like proliferation rate of tumor cells belonging to a particular type of tumour, the task will be very easy in dealing with cancer related research work and also in treatment of cancer by any method of treatment. The proliferation rates of the different tumour cells, the range values of the tumour proliferation rates and confidence intervals for population

* Associate Professor, Deccan school of Management, Hyderabad, India.

** Retired Professor, MJ College of Engineering & Tecnology, Hyderabad, India.

proliferation rates with 0.90, 0.95 and 0.99 confidence levels were estimated from the tumor doubling times with the help of tumour growth equation and statistical theory from the experimental data.

2. Literature Review

Cancer research related to tumour spheroids and mathematical modeling of tumor growth dates back to late 1960's. Growth of multi cell tumours were examined by Burton A.C. (1966), Judah Folkman and Mark Hochberg (1973), H.P. Greenspan (1973), R.M. Sutherland (1974), etc. Mathematical models have been developed by considering the behaviour of multi cell tumour spheroids *in vitro* experiments using diffusion theory. Burton A.C (1966) developed a model using diffusion theory and showed that the growth of solid tumours is not exponential but it follows Gompertzian relation. The doubling times of various histological types of human tumours were studied by Malaise et al, (1973) [7], experimental potential doubling times of human tumours were obtained by E.H. Cooper, A.J. Bedford and T.E. Kenny [4], the experimental doubling times of primary and metastatic human tumours were calculated by Renato Baserga [8], range of doubling times of were studied by Esmael Mehrara et. al [3] and doubling times of cell lines from various panels based on clinical research were taken from the website of National cancer institute of United States of America[9].

3. Methodology

By assuming only proliferating cells contribute to the growth of the tumour spheroid and considering a total N number of cells with volume v of each cell in the tumor spheroid containing only N_p proliferating cells with proliferation rate s , the increase in total number of cells N in time Δt is taken as ΔN . The ΔN can be calculated as the product of number of proliferating cells, proliferation rate and time.

$$\Delta N = N_p \times s \times \Delta t, \quad \Delta N = (s \cdot \Delta t) N_p.$$

If we take $\Delta t \rightarrow 0$, $\frac{\Delta N}{\Delta t} = s \cdot N_p$ (i.e) $\frac{dN}{dt} = s \cdot N_p$ (s is the proliferation rate which can be taken as rate constant of cell production). In place of individual cells, if we consider volume as whole, it will become $\frac{dV}{dt} = s \cdot V_p$ (where $V_p = v \cdot N_p$). If all the cells are proliferating or when the tumour is small, we consider $N = N_p$ and $V = V_p$. By considering the initial radius of tumour spheroid as R_0 , $\frac{dV}{dt} = s \cdot \frac{4\pi}{3} R_0^3$. This will lead to the differential equation $\frac{dR_0}{dt} = \frac{s}{3} R_0$. This is a first order linear differential equation whose solution will be $R_0 = k \cdot e^{\frac{st}{3}}$. By taking initial conditions, at time $t = 0$, $R_0(0) = R_0$, gives $k = R_0(0)$. The solution can be taken as $R_0(t) = R_0(0)e^{\frac{st}{3}}$. Since the volume ($V = \frac{4\pi}{3} R_0^3$) of the tumour spheroid is directly proportional to the radius, we get $V(t) = V(0)e^{st}$. Let us consider the time taken by the tumour to double its volume is t_d . Then the equation $V(t) = V(0)e^{st}$ will become $2V(t) = V(0)e^{st_d}$. Taking natural logarithms on both sides and solving, we get $s = \frac{\ln 2}{t_d}$. The advantage of the mathematical modeling is to predict the result with out going for the experimental work. The proliferation rates can be calculated from available tumour doubling times and other parameters depending on the proliferation rate can be estimated with out waiting for a lengthy time.

In the experiments, the time taken for the cells to double their size assuming no cell loss is considered as potential doubling time t_{pot} and if there is cell loss, the time taken to double their size is considered as doubling time t_d . In this study, the time taken to double the size of the tumor with or with out cell loss is considered as t_d . In some experiments, instead of giving single value to doubling time, a range of values is used. In such cases, interval estimate of the proliferation rate is calculated. Since availability of a particular type of tumour cell is a constraint to the investigator, the numbers of tumours are less than 30, it is considered as small sample with size $n < 30$. In sampling theory, by considering the characteristics of the sample, we can make inferences about population parameter. The experimental results are used to estimate the unknown parameter (mean proliferation rate) of the tumour population in the form of interval estimate. While finding interval estimates, the confidence levels of 90%, 95% and 99% are considered. With respect to 90% confidence level, we can say the interval estimate will include the true population parameter 90% of the time and 10% ($\alpha = 0.10$) of the time it may not be. In these cases, α is considered as Significance level. The same assumption applies to 95% and 99% confidence interval estimates also with ($\alpha = 0.05$ & 0.01) respectively. Since $n < 30$, student's t distribution is used with the formula [Mean of the sample $\pm (t) \cdot (\text{standard error of mean})$] with degrees of freedom ($n - 1$). To visualize and to have clear nature of the tumour cells of similar type, scatter diagrams are obtained with the help of MATLAB.

4. Results and Conclusions

1. The experimental data related to doubling times of various histological types of human tumours by Malaise et al, (1973) published in European journal of cancer, vol 9, 305-312 with reference from the book “An introduction to radiobiology” by A.H.W. Nias is taken for estimating of their corresponding proliferation rates and are shown in the table 1.

2. The proliferation rates of human tumours by using experimental potential doubling time data of human tumours by E.H. Cooper, A.J. Bedford and T.E. Kenny in ‘cell death in normal and malignant tissues’ from “Advances in cancer research; volume 21” are shown in the table 2.

3. The experimental doubling times of primary and metastatic human tumours from the book “The biology of cell reproduction” by Renato Baserga are used to calculate proliferation rates which are shown in the table 3.

4. Clinical data related to tumour doubling times from Esmael Mehrara et. al which contains range of values for doubling times and some similar type of tumours with different researchers is taken to calculate proliferation rate range in the table 4.

5. Much more detailed information on doubling times of cell lines from various panels based on extensive research work is taken from website of National cancer institute of United States of America, to calculate proliferation rates and shown in the tables 5&6.

6. For the nine panels of tumours with 61 different cells mentioned in the table 5 and table 6, Interval estimates of population parameter (mean proliferation rate of the panel) is obtained by calculating sample mean, sample standard deviation and standard error of the mean with confidence levels 0.90, 0.95 & 0.99 respectively which are shown in the table 7.

7. For the purpose of comparison between different panels and to visualize variations within the panels, scatter diagrams of 9 panels were obtained with the help of MATLAB which is shown in the figure 8.

8. From the data in the tables 4, 5, 6 and 7 it was clear that even for the tumours of similar type, the doubling times are not same. But they may lie between certain limits. The same observation can be seen even for proliferation rates as they have been calculated from tumour doubling times. The results can be clearly seen in the scatter diagrams in the figure 8 which are scattered between certain limits without coincidence.

9. The advantage of mathematical modeling is to predict the result without going for the experimental work. If the proliferation rates are known, the rate in change of volume over a period of time can be estimated with the initial volume of the tumour.

| Histological type | Doubling time (days) | <i>Proliferation rate (s)</i> |
|--------------------------|---------------------------------|--|
| Embryonal tumour | 27 | 0.02567 |
| Malignant lymphoma | 29 | 0.02390 |
| Sarcoma | 41 | 0.01690 |
| Squamous cell carcinoma | 58 | 0.01195 |
| Adenocarcinoma | 83 | 0.00835 |

Table1. Table showing estimated proliferating rates of various histological types of human tumours.

| Lymphomas | Number of tumours measured | Potential doubling Times (days) | <i>Proliferation rate (s)</i> |
|---------------------------|----------------------------|---------------------------------|---------------------------------|
| Hodking's disease | 10 | 1.8 | 0.38508 |
| Recticulum cell sarcoma | 13 | 1.6 | 0.43322 |
| Lymphatic lymphoma | 12 | 1.6 | 0.43322 |
| Histiocytic - lymphocytic | 5 | 4.0 | 0.17329 |
| Burkitt tumour (1) | 26 | 1.4 | 0.49510 |
| Burkitt tumour (2) | 23 | 1.9 | 0.36481 |
| Carcinoma of bladder | 32 | 15.0 | 0.04621 |
| Carcinoma of colon | 31 | 10.4 | 0.06665 |
| Carcinoma of the breast | 38 | 43 | 0.01612 |

Table2. Table showing estimated proliferating rates of human tumours corresponding to their potential doubling times

| Type of Tumour | Mean volume doubling Time in days | <i>Proliferation rate (s)</i> |
|-------------------------------------|-----------------------------------|---------------------------------|
| Primary tumours | | |
| Squamous cell carcinoma of the lung | 84 | 0.00825 |
| Adenocarcinoma of colon and rectum | 632 | 0.00110 |
| Carcinoma of the breast | 96 | 0.00722 |
| Sarcoma of bone | 63 | 0.01100 |
| Metastases in the lung, from | | |
| Adenocarcinoma of colon and rectum | 95 | 0.00730 |
| Carcinoma of the breast | 73 | 0.00950 |
| Ewing's sarcoma | 17 | 0.04077 |
| Sarcoma of bone | 30 | 0.02310 |
| Melanoma | 53 | 0.01308 |
| Lymphoma | 27 | 0.02567 |

Table3. Table showing estimated proliferation rates of primary and secondary tumours calculated from their mean volume doubling time.

| S.No | Reference | Tumour | Sample Size (n) | Doubling time range (t_d) | Proliferation Rate range (s) |
|------|------------------------------------|--|---------------------|-------------------------------|----------------------------------|
| 1 | (Nishida, Kaneko et al. 1999) | Pancreatic carcinoma | 12 | 18-232 | 0.0030 - 0.0385 |
| 2 | (Furukawa, Iwata et al. 2001) | Pancreatic carcinoma | 9 | 64-255 | 0.0027 - 0.0108 |
| 3 | (Wang, Some et al. 2000) | Adenocarcinoma (lung) | 8 | 72-131 | 0.0053 - 0.0096 |
| 4 | (Winer-Muram, Jennigs et al. 2002) | Adenocarcinoma (lung) | 15 | (-1350)-964 | -0.0005 - 0.0007 |
| 5 | (Winer-Muram, Jennigs et al. 2002) | Bronchioalveolar(lung) | 9 | 36-1092 | 0.0006 - 0.0193 |
| 6 | (Winer-Muram, Jennigs et al. 2002) | Squamous cell lung carcinoma | 16 | (-1214)-225 | -0.0006 - 0.0031 |
| 7 | (Winer-Muram, Jennigs et al. 2002) | Non small cell lung carcinoma | 6 | 48-698 | 0.0100 - 0.0144 |
| 8 | (EI Sharouni, Kal et al. 2003) | Non small cell lung cancer | 18 | 8-171 | 0.0040 - 0.0866 |
| 9 | (Wang, Sone et al. 2000) | Small cell lung cancer | 4 | 54-132 | 0.0052 - 0.0128 |
| 10 | (Blomqvist, Wiklund et al. 1993) | Sarcoma(lungmetastases) | 21 | 7-1172 | 0.0006 - 0.0990 |
| 11 | (Nakajima, Moriguchi et al. 2002) | Hepatocellular carcinoma (well differentiated) | 19 | 38-274 | 0.0025 - 0.0182 |
| 12 | (Saito, Matsuzaki et al. 1998) | Hepatocellular carcinoma (well differentiated) | 15 | 76-720 | 0.0010 - 0.0091 |
| 13 | (Nakajima, Moriguchi et al. 2002) | Hepatocellular carcinoma (moderately differentiated) | 9 | 17-91 | 0.0076 - 0.0408 |
| 14 | (Saito, Matsuzaki et al. 1998) | Hepatocellular carcinoma (moderately differentiated) | 5 | 94-380 | 0.0018 - 0.0074 |
| 15 | (Nakajima, Moriguchi et al. 2002) | Hepatocellular carcinoma (poorly differentiated) | 5 | 20-78 | 0.0089 - 0.0347 |

Table4. Table showing number of tumours, doubling time range and their proliferation range including references

| S.No | Cell Line Name | Panel Name | Doubling time | Proliferation rate (s) |
|------|----------------|---------------------|---------------|--------------------------|
| 1 | CCRF-CEM | Leukemia | 26.7 | 0.02596 |
| 2 | HL-60(TB) | Leukemia | 28.6 | 0.02424 |
| 3 | K-562 | Leukemia | 19.6 | 0.03536 |
| 4 | MOLT-4 | Leukemia | 27.9 | 0.02484 |
| 5 | RPMI-8228 | Leukemia | 33.5 | 0.02069 |
| 6 | SR | Leukemia | 28.7 | 0.02415 |
| 7 | A549/ATCC | Non-Small Cell Lung | 22.9 | 0.03027 |
| 8 | EKVX | Non-Small Cell Lung | 43.6 | 0.01590 |
| 9 | HOP-62 | Non-Small Cell Lung | 39 | 0.01777 |
| 10 | HOP-92 | Non-Small Cell Lung | 79.5 | 0.00872 |
| 11 | NCI-H226 | Non-Small Cell Lung | 61 | 0.01136 |
| 12 | NCI-H23 | Non-Small Cell Lung | 33.4 | 0.02075 |
| 13 | NCI-H322M | Non-Small Cell Lung | 35.3 | 0.01964 |
| 14 | NCI-460 | Non-Small Cell Lung | 17.8 | 0.03894 |
| 15 | NCI-H522 | Non-Small Cell Lung | 38.2 | 0.01814 |
| 16 | COLO 205 | Colon | 23.8 | 0.02912 |
| 17 | HCC-2998 | Colon | 31.5 | 0.02200 |
| 18 | HCT-116 | Colon | 17.4 | 0.03983 |
| 19 | HCT-15 | Colon | 20.6 | 0.03365 |
| 20 | HT29 | Colon | 19.5 | 0.03555 |
| 21 | KM12 | Colon | 23.7 | 0.02925 |
| 22 | SW-620 | Colon | 20.4 | 0.03398 |
| 23 | SF-268 | CNS | 33.1 | 0.02094 |
| 24 | SF-295 | CNS | 29.5 | 0.02350 |
| 25 | SF-539 | CNS | 35.4 | 0.01958 |
| 26 | SNB-19 | CNS | 34.6 | 0.02003 |
| 27 | SNB-75 | CNS | 62.8 | 0.01104 |
| 28 | U251 | CNS | 23.8 | 0.02912 |
| 29 | LOXIMVI | Melanoma | 20.5 | 0.03381 |
| 30 | MALME-3M | Melanoma | 46.2 | 0.01500 |
| 31 | M14 | Melanoma | 26.3 | 0.02636 |

Table5. Table showing cell line name, panel name with their doubling time and estimated proliferation rates.

| S.No | Cell Line Name | Panel Name | Doubling time | Proliferation rate (s) |
|------|-----------------|------------|---------------|------------------------|
| 32 | MDA-MB-435 | Melanoma | 25.8 | 0.02687 |
| 33 | SK-MEL-2 | Melanoma | 45.5 | 0.01523 |
| 34 | SK-MEL-28 | Melanoma | 35.1 | 0.01975 |
| 35 | SK-MEL-5 | Melanoma | 25.2 | 0.02751 |
| 36 | UACC-257 | Melanoma | 38.5 | 0.01800 |
| 37 | UACC-62 | Melanoma | 31.3 | 0.02215 |
| 38 | IGR-OVI | Ovarian | 31 | 0.02236 |
| 39 | OVCAR-3 | Ovarian | 34.7 | 0.01998 |
| 40 | OVCAR-4 | Ovarian | 41.4 | 0.01674 |
| 41 | OVCAR-5 | Ovarian | 48.8 | 0.01420 |
| 42 | OVCAR-8 | Ovarian | 26.1 | 0.02656 |
| 43 | NCI/ADR-RES | Ovarian | 34 | 0.02039 |
| 44 | SK-OV-3 | Ovarian | 48.7 | 0.01423 |
| 45 | 786-0 | Renal | 22.4 | 0.03094 |
| 46 | A498 | Renal | 66.8 | 0.01038 |
| 47 | ACHN | Renal | 27.5 | 0.02521 |
| 48 | CAKI-1 | Renal | 39 | 0.01777 |
| 49 | RXF 393 | Renal | 62.9 | 0.01102 |
| 50 | SN12C | Renal | 29.5 | 0.02350 |
| 51 | TK-10 | Renal | 51.3 | 0.01351 |
| 52 | UO-31 | Renal | 41.7 | 0.01662 |
| 53 | PC-3 | Prostate | 27.1 | 0.02558 |
| 54 | DU-145 | Prostate | 32.3 | 0.02146 |
| 55 | MCF7 | Breast | 25.4 | 0.02729 |
| 56 | MDA-MB-231/ATCC | Breast | 41.9 | 0.01654 |
| 57 | MDA-MB-468 | Breast | 62 | 0.01118 |
| 58 | HS 578T | Breast | 53.8 | 0.01288 |
| 59 | MDA-N | Breast | 22.5 | 0.03081 |
| 60 | BT-549 | Breast | 53.9 | 0.01286 |
| 61 | T-47D | Breast | 45.5 | 0.01528 |

Tabl6. Table showing cell line name, panel name with their doubling time and estimated proliferation rates

| S. No | Panel Name | Average (\bar{s}) | Standard deviation (σ_s) | 90% Confidence Interval $(\alpha = 0.10)$ | 95% Confidence Interval $(\alpha = 0.05)$ | 99% Confidence Interval $(\alpha = 0.01)$ |
|-------|---------------------|---------------------|---------------------------------|---|---|---|
| 1 | Leukemia | 0.0259 | 0.0050 | 0.0218 -- 0.0300 | 0.0207 -- 0.0311 | 0.0177 – 0.0341 |
| 2 | Non-Small Cell Lung | 0.0206 | 0.0084 | 0.0154 -- 0.0258 | 0.0141 – 0.0271 | 0.0140 – 0.0272 |
| 3 | Colon | 0.0319 | 0.0057 | 0.0277 – 0.0361 | 0.0266 – 0.0372 | 0.0234 – 0.0399 |
| 4 | CNS | 0.0207 | 0.0059 | 0.0158 – 0.0256 | 0.0145 – 0.0269 | 0.0110 – 0.0304 |
| 5 | Melanoma | 0.0227 | 0.0064 | 0.0187 – 0.0267 | 0.0178 – 0.0276 | 0.0156 – 0.0298 |
| 6 | Ovarian | 0.0192 | 0.0045 | 0.0159 – 0.0225 | 0.0150 – 0.0234 | 0.0129 – 0.0255 |
| 7 | Renal | 0.0186 | 0.0073 | 0.0137 – 0.0235 | 0.0125 – 0.0247 | 0.0096 – 0.0276 |
| 8 | Prostate | 0.0235 | 0.0029 | 0.0106 – 0.0364 | 0.0000 – 0.0756 | 0.0000 – 0.2835 |
| 9 | Breast | 0.0181 | 0.0077 | 0.0124 – 0.0238 | 0.0110 – 0.0252 | 0.0073 – 0.0289 |

Table7. Table showing average, standard deviation of proliferation rates with their confidence intervals




Figure8. Scatter diagrams showing proliferation rates of cell lines from different panels

4. References

- [1] A.C. Burton, Rate of growth of solid tumours as a problem of diffusion, *Growth* **30**(1966), pp 157-176.
- [2] Folkman J, and M. Hochberg, (1973), Self regulation of growth in three dimensions. *J. Exp .Med* **138**: pp 745-753
- [3] Esmael Mehrara et al, Specific Growth Rate Verses Doubling Time for Quantitative Characterization Of Tumor growth rate “*Advances in cancer research*”; 2007; **67**: pp 3970-3975
- [4] E.H. Cooper, A.J. Bedford and T.E. Kenny in ‘cell death in normal and malignant tissues’ “*Advances in cancer research*; volume 21” 1975; pp 21:59-120
- [5] H.P. Greenspan, Models for the growth of a solid tumor by diffusion, *Stud.Appl.Math.***52** (1972), pp 317-340.
- [6] H.P . Greenspan, On the growth and stability of cell cultures and solid tumors, *J. Theor. Biol.***56** (1976), pp 229-242
- [7] A.H.W. Nias, An Introduction to Radiobiology, 2nd Edition, John Wiley & Sons (1998)
- [8] Renato Baserga, The Biology of Cell Reproduction, Harvard University Press, (1985)
- [9] https://ntp.cancer.gov/discovery_development/nci-60/cell_list.htm

Note: Above article is a part of the research work carried out in Ph.D curriculam under Osmania University in Department of Mathematics with topic “Theoretical Study of Problems in Life sciences and Medicine”.